To evaluate the effect of the GALNS enzyme released by CRISPR/nCas9-edited CD34+ cells, we co-cultured these cells with human MPS IVA fibroblasts for one month and assessed GALNS enzyme activity, along with classical LSD biomarkers. The gene discussed is CD34; the disease is mucopolysaccharidosis type 4A.